Review of our business Shire delivers double digit product sales growth and 23% increase in Non GAAP earnings.
Overview Shire is a leading specialty biopharmaceutical company that focuses on developing and marketing innovative specialty medicines that address significant unmet patient needs.
The Company has grown through acquisition, completing a series of major transactions that have brought therapeutic, geographic and pipeline growth and diversification.
The Company will continue to evaluate companies, products and pipeline opportunities that offer a good strategic fitand have the potential to deliver demonstrable value to all of the Companys stakeholders: patients, physicians, policy Summary makers, payors, investors and employees.
Shire has delivered excellent financial The Companys vision is to transform the resultsin 2013 and now has the lives of people around the world whose foundationsin place for further future health is impacted by rare and other growth.
Our sharpened strategic focus specialized conditions, through providing innovative treatments.
The Company will andstrong operational discipline have execute on its vision through its strategy enabled us to deliver double digit product and business model.
For further details sales growth and Non GAAP earnings per ofShires strategy and business model, refer to page 18.
Weve generated strong cash flows during the year, which have helped ustostrengthen our balance sheet.
Overview Double digit product sales growth drives Non GAAP EPS growth of 23% Step change in operating leverage Expecting 2014 Non GAAP EPS growth at a similar level to 2013 Graham Hetherington Chief Financial Officer Repositioned for further growth 34 SHIRE PLC ANNUAL REPORT 2013 WWW.
COM Governance Financial statements Other information Strategic report Through deep understanding of patients increase in Medicaid rebate rates and Markets needs, the Company is able to: extended Medicaid rebates to those Shires current portfolio of approved products provided through Medicaid products focuses on the following markets: serve patients with high unmet needs managed care organizations.
Rare Diseases, Neuroscience and inselect, commercially attractive specialty Thelegislation also imposed excise fees Gastrointestinal GI diseases.
Shire also therapeutic areas: tobe paid by both pharmaceutical has a number of marketed products for manufacturers from 2011 and medical other therapeutic areas from which it drive optimum performance of its device companies from 2013.
The CMS generates product revenues or royalties marketed products to serve are also increasingly bundling drug from third parties.
In 2013 Shire derived patientstoday: reimbursement into procedure costs, which 41% of product sales from Neuroscience build its pipeline of innovative specialist can severely decrease the reimbursement products, 33% from Rare Diseases treatments through both R&D and rates to physicians for some manufacturers products, 17% from GI products and 9% Business Development activities drugs, biologicals and medical devices.
from products addressing other toenable the Company to serve patients The impact of these recent changes to US therapeutic areas.
Shires early stage in the future.
healthcare legislation, and other healthcare research is focused on rare diseases.
reforms in the rest of the world, has not to Shires in-licensing and acquisition efforts Shire has grown through acquisition which date had a material impact on the are focused on products in specialist has brought therapeutic, geographic and Companys results of operations.
markets with strong intellectual property pipeline growth and diversification.
For protection or other forms of market The healthcare industry is also example the recent acquisitions of Ferrokin exclusivity and global rights.
Shire believes experiencing: Biosciences Inc Ferrokin in 2012 and that a carefully selected and balanced Lotus Tissue Repair, Premacure and pressure from governments and health portfolio of products with strategically SARcode in 2013 provide potential access care providers to keep prices low while aligned and relatively small-scale sales to new markets such as ophthalmology, increasing access to drugs: forces will deliver strong results.
The acquisition of ViroPharma, which increasing challenges from third party Substantially all of the Companys closed in January 2014, expands Shires payors for products to have revenues, expenditures and net assets Rare Diseases portfolio including adding demonstrable clinical benefit, with pricing areattributable to the R&D, manufacture, CINRYZE, a leading currently marketed and reimbursement approval becoming sale and distribution of pharmaceutical product for the prophylactic treatment increasingly linked to a products clinical products within one reportable segment.
effectiveness and impact on overall costs The Company also earns royalties where of patient care: Shire has out-licensed products to third In 2013 Shire derived 30% of product sales parties which are recorded as revenues.
Shire has ongoing increased R&D costs, because commercialization and late-stage development programs are typically Revenues are derived primarily from two development activities, which are expected larger and take longer to get approval sources sales of the Companys own to further supplement the diversification of from regulators: products and royalties: revenues in the future, including the challenges to existing patents from 96% 2012: 94% of total revenues are following: generic manufacturers: derived from product sales: and filing in 2013 of an application in Japan for governments and healthcare systems 3% of total revenues are derived from the approval of VPRIV for the treatment of favoring earlier entry of low cost generic royalties 2012: 5%.
Gaucher disease: drugs: and The markets in which the Company filing in 2013 of an application in Japan for higher marketing costs, due to increased conducts its business are highly the approval of XAGRID for the treatment competition for market share.
of elevated platelet counts in at risk essential thrombocythemia patients: and Shires strategy has been developed to There is increasing legislation both in the address these industry-wide competitive US and the rest of the world which is INTUNIV Phase 3 clinical program to pressures.
This strategy has resulted in a placing downward pressure on the net support submission of an MAA in the EU.
series of initiatives in the following areas: pricing of pharmaceutical products and medical devices.
For example the US government passed healthcare reform legislation in 2010 which included an WWW.
COM ANNUAL REPORT 2013 SHIRE PLC 35 Review of our business continued R&D Shires R&D costs in 2013 included Shire is engaged in various legal The Company reorganized its R&D efforts expenditure on programs in all stages of proceedings with generic manufacturers in 2013, combining the R&D organizations development.
The following table provides with respect to its VYVANSE, LIALDA and of its former divisions into a single One an analysis of the Companys direct R&D ADDERALL XR patents.
For more detail of Shire R&D organization focused around a spend categorized by development stage, current patent litigation, see Note 19 to the prioritized portfolio of development and based upon the development stage of consolidated financial statements.
Shire has focused its each program as at December 31, 2013: Business Development R&D efforts on five therapeutic areas: Rare Shire seeks to focus its business 2013 diseases, Neuroscience, GI, Hematology development activity on the acquisition and Year to December 31, $M and Ophthalmology.
Shire concentrates its in-licensing of products and compounds resources on obtaining regulatory approval Early stage programs 102 which offer a good strategic fit and have for later-stage pipeline products within Late stage programs 327 the potential to deliver demonstrable value these therapeutic areas and focuses its Currently marketed products 179 to all of the Companys stakeholders.
early stage research activities primarily in Total 608 rare diseases.
Recent mergers or acquisitions On January 24, 2014 Shire completed Evidence of the successful progression of In addition to the above, the Company theacquisition of ViroPharma which added the late stage pipeline can be seen in the recorded R&D employee costs of $282 a marketed product for the prophylactic granting of approval and associated million in 2013 and other indirect R&D treatment of HAE, CINRYZE, as well as launches of the Companys products over costs comprising depreciation and anumber of other marketed products the last five years.
In this time several impairment charges of $43 million.
anda pipeline of product candidates products have received regulatory intherare disease area.
approval including: in the US, INTUNIV in Patents and market exclusivity 2009, VPRIV in 2010, and FIRAZYR in The loss or expiration of patent protection In 2013, Shire acquired: 2011: in the EU, VPRIV in 2010 and or regulatory exclusivity with respect to any SARcode which added SHP606 to the ELVANSE TYVENSE in 2012: in Canada, of the Companys major products could Shire portfolio SHP606 is currently in VYVANSE in 2010. have a material adverse effect on the Phase 3 development for the treatment Companys revenues, financial condition Prior to the One Shire R&D reorganization, ofDry Eye disease.
and results of operations, as generic or the Companys management reviewed biosimilar products may enter the market.
Premacure which added SHP607 to the R&D expenditure by operating segment.
Companies selling generic products often Shire portfolio SHP607 is currently in Following the One Shire R&D do not need to complete extensive clinical Phase 3 for the prevention of ROP.
reorganization, Shires management studies when they seek registration of a reviews direct costs for R&D projects by Lotus Tissue Repair which added global generic or biosimilar product and development phase.
rights to a protein replacement therapy accordingly, they are generally able to sell inpre-clinical development, for the generic versions of the Companys treatment of DEB.
products at a much lower price.
In 2012, Shire acquired: As expected, in 2009 Teva and Impax commenced commercial shipments of FerroKin which added SHP602 to the their authorized generic versions of Shire portfolio SHP602 is in Phase 2 for ADDERALL XR, which led to lower sales the treatment of iron overload following ofbranded ADDERALL XR compared numerous blood transfusions.
tothe period prior to the authorized Substantially all the assets and certain generic launch.
liabilities of Pervasis Therapeutics Inc.
In 2011, authorized generic and generic which added VASCUGEL now SHP613 versions of the Companys CARBATROL to the Shire portfolio SHP613 is in Phase and REMINYL products respectively were 2 development for acute vascular repair.
launched, which led to lower sales of these branded products compared to the period before loss of exclusivity.
36 SHIRE PLC ANNUAL REPORT 2013 WWW.
COM Governance Financial statements Other information Strategic report Collaboration and licensing activity The impact of the prioritization and Shire has also entered into a number of rationalization of the Companys collaboration and license agreements in development portfolio means many of recent years, including: theR&D programs currently run from Basingstoke, UK will cease.
Taken together a collaboration and license agreement with the overall streamlining of the R&D with Sangamo to develop therapeutics organization, this has resulted in a for hemophilia and other monogenic significant number of R&D roles in diseases based on Sangamos ZFP Basingstoke being eliminated and some technology in 2012: positions being re-located.
A small number of functional roles that support R&D in a worldwide exclusive license from IGAN Basingstoke have also been affected.
Biosciences, Inc. IGAN to develop and commercialize protease-based In addition the Company announced plans therapeutics for the treatment of IgA to re-locate its international commercial nephropathy, a rare kidney disease in hub from Nyon, Switzerland to Zug, 2012: and Switzerland.
All Nyon based employees have been impacted by the One Shire Shionogi co-development and cotransition and the move to Zug.
Shire is commercialization agreement in 2012 for planning for the new Zug office to be ready VYVANSE and INTUNIV in Japan.
for occupancy in summer 2014, and will Organization and Structure phase out the Nyon office over a On May 2, 2013, the Company announced reasonable period of time to enable that there would be a reorganization of the employees and their families to manage Companys business to integrate its their re-locations.
Specialty Pharmaceuticals SP, Human On October 22, 2013 Shire announced Genetic Therapies HGT and that it had decided to discontinue the Regenerative Medicine RM business construction of its new manufacturing units and reportable segments into a facility in San Diego.
On January 16, 2014, simplified One Shire organization in order the Company sold and transferred certain to drive future growth and innovation.
of the assets relating to the manufacturing, Consequently the SP, HGT and RM marketing, sale and distribution of segments no longer exist.
Shire now DERMAGRAFT to Organogenesis Inc. For comprises a single operating and further information, see Note 9, Results of reportable segment.
For further details see discontinued operations and assets held Note 25 Segment reporting to the for sale to the consolidated financial consolidated financial statements.
On November 7, 2013, the Company On January 23, 2013 Shire announced that announced that, as part of the One Shire it had decided to proceed with a collective reorganization, the Company had dismissal and business closure at its site in undertaken a review of all of Shires Turnhout, Belgium.
This decision followed pipeline programs to identify those projects the conclusion of an information and that fit with Shires new strategic direction consultation process.
Shire continues to and have an acceptable likelihood of sell RESOLOR in Europe and the supply of success.
Shires pre-clinical investments RESOLOR for patients in Europe who rely will now be primarily focused on rare on the medicine will not be affected.
The diseases, meaning that the majority of closure of the Turnhout site was completed other pre-clinical projects will not continue.
Several clinical programs have also been discontinued.
COM ANNUAL REPORT 2013 SHIRE PLC 37 Review of our business continued Results of operations for the year to $1,734million 2012: $1,045 million, December 31, 2013 primarily dueto the strong growth in $4,757m Financial highlights for the year to product sales and an overall reduction in December 31, 2013 are as follows: total operating expenses in 2013 compared Product sales from continuing to 2012 as the Company focuses on Product sales from continuing operations delivering efficient growth.
Operating operations 2012: $4,253m in 2013 were up 12% to $4,757 million expenses in 2013 include a net credit of 2012: $4,253 million.
$159 million due to change in the fair value of contingent consideration liabilities, in The strong growth in product sales from particular relating to the acquisition of continuing operations was driven by SARcode following the release of top-line VYVANSE up 19% to $1,228 million, $4,934m Opus-2.
Operating expenses in 2012 LIALDA MEZAVANT up 32% to $529 Total revenues from continuing include impairment charges of $197.9 million, VPRIV up 12% to $343 million, million in 2012 related to RESOLOR INTUNIV up 16% to $335 million and operations 2012: $4,527m intangible assets.
Research and FIRAZYR up 102% to $235 million.
Development expenditure decreased by Total revenues from continuing operations 2%.
were up 9% to $4,934 million 2012: Diluted earnings per Ordinary Share $4,527 million as the growth in product fromcontinuing operations increased $1,734m sales was partially offset, as expected, 74%to $2.45 2012: $1.41 due to the bylower royalties and other revenues US GAAP operating income higher operating income from continuing down 36%.
operations and a lower effective tax from continuing operations Operating income from continuing rateof16% 2012: 20%.
operations in 2013 was up 66% to 2012: $1,045m Total revenues The following table provides an analysis of the Companys total revenues by source: 2013 2012 Change Year to December 31, $M $M % Product sales 4,757.5 4,252.9 12% Royalties 153.7 241.6 -36% Other revenues 23.1 32.9 -30% Total 4,934.3 4,527.4 9% 38 SHIRE PLC ANNUAL REPORT 2013 WWW.
Exit market share represents the average US market share in the month ended December31,2013.
2 IMS NPA Data not available.
3 Not sold in the US in the year to December 31, 2013.
4 The Companys management analyzes product sales and revenue growth for certain products sold in markets outside of the US on a constant exchange rate CER basis, so that product sales and revenue growth can be considered excluding movements in foreign exchange rates.
Product sales and revenue growth on a CER basis is a Non GAAP financial measure Non GAAP CER, computed by comparing 2013 product sales and revenues restated using 2012 average foreign exchange rates to 2012 actual product sales and revenues.
This Non GAAP financial measure is used by Shires management, and is considered to provide useful information to investors about the Companys results of operations, because it facilitates an evaluation of the Companys year-on-year performance on a comparable basis.
1 VYVANSE ADHD REPLAGAL Fabry disease 2012, together with price increases.
VYVANSE product sales grew strongly REPLAGAL sales were down 6% These positive factors were partially offset 19% in 2013 primarily as a result of price compared to 2012 down 4% on a Non by higher sales deductions in 2013 increases as well as higher prescription GAAP CER basis as sales in 2013 were compared to 2012. demand, primarily due to growth in the impacted by foreign exchange, pricing Further information about litigation USADHD market 6%.
pressure primarily in Europe andslightly proceedings regarding INTUNIV can be lower volumes due to the return of Litigation proceedings regarding VYVANSE found in see Note 19 to the consolidated competition to the Fabry market.
Further information about this financial statements.
litigation can be found in Note 19 to the ADDERALL XR ADHD PENTASA Ulcerative Colitis consolidated financial statements.
ADDERALL XR product sales decreased PENTASA product sales were up 6% as 12% in 2013 as a result of higher sales ELAPRASE Hunter syndrome the benefit of price increases was partially deductions, partially offset by the effect of Reported ELAPRASE sales growth 10% offset by higher sales deductions in 2013 higher stocking in 2013 compared to 2012. was driven by an increase in the number of as compared to 2012. patients on therapy.
Litigation proceedings regarding FIRAZYR Hereditary Angioedema ADDERALL XR are ongoing.
Further LIALDA MEZAVANT Ulcerative colitis FIRAZYR sales growth 102% compared information about this litigation and the The growth in product sales for LIALDA to 2012 was primarily driven by the US Impax settlement, can be found in Note 19 MEZAVANT 32% in 2013 was primarily market, where we continue to see both to the consolidated financial statements.
driven by higher market share in the US, good growth in new patients and the effects of which were partially offset VPRIV Gaucher disease increased levels of repeat usage by byhigher sales deductions in 2013 as Reported VPRIV sales growth of 12% was existing patients.
compared to 2012. driven by an increase in the number of 1 patients on therapy.
The actual net effect of price increases on current Litigation proceedings regarding LIALDA period net sales compared to the comparative MEZAVANT are ongoing.
Further INTUNIV ADHD period is difficult to quantify due to the various information about this litigation can be INTUNIV product sales were up 16% managed care rebates, Medicaid discounts, otherdiscount programs in which the Company found in Note 19 to the consolidated compared to 2012, driven by growth in US participates and fee for service agreements with financial statements.
prescription demand up 9% compared to wholesalers customers.
COM ANNUAL REPORT 2013 SHIRE PLC 39 Review of our business continued Royalties determined that the goodwill attributable tothe RM business unit was impaired.
December 31, December 31, Following the divestment of DERMAGRAFT 2013 2012 Change on January 16, 2014 the Company has $M $M % reclassified $191.8 million of the impairment FOSRENOL 48.1 53.3 -10% charge being the portion of the RM 3TC and ZEFFIX 46.7 91.6 -49% reporting unit goodwill impairment charge ADDERALL XR 27.6 70.3 -61% that related to the DERMAGRAFT Other 31.3 26.4 19% business to discontinued operations.
Total 153.7 241.6 -36% Reorganization costs from continuing operations Royalties from ADDERALL XR in 2013 Companys continuing investment in For the year to December 31, 2013 Shire were significantly impacted by the lower anumber of targeted R&D programs, recorded reorganization costs of $88.2 royalty rate payable on sales of authorized particularly new uses for LDX and other million 2012: $nil comprising costs relating generic ADDERALL XR by Impax, following recently acquired assets including to the One Shire reorganization $64.6 the launch of a new generic version of SHP606 Lifitegrast, SHP607 for million, which included involuntary ADDERALL XR late in the second quarter theprevention of ROP and SHP608 termination benefits and other of 2012 as well as by Impaxs lower market forthetreatment of DEB.
reorganization costs of which share in 2013 versus 2012. approximately $42 million was paid in cash R&D in the year to December 31, 2013 during 2013 as the Company transitions to Royalties from 3TC and ZEFFIX in 2013 included depreciation of $23.3 million a new operating structure, and the cost of were lower, as 2012 included one-time 2012: $22.5 million.
closing the Companys facility at Turnhout, royalty income of $38 million in respect SG&A from continuing operations Belgium $23.6 million.
ofprior periods due to resolution of a SG&A expenditure decreased to $1,651.3 disagreement with GlaxoSmithKline and Integration and acquisition costs from million 35% of product sales for the year ViiV Healthcare.
continuing operations to December 31, 2013 from $1,948.0 For the year to December 31, 2013 Cost of product sales from continuing million 46% of product sales in the theCompany recorded a net credit of operations corresponding period in 2012.
In the year $134.1million in integration and acquisition Cost of product sales increased to $670.8 to December 31, 2012 SG&A included costs 2012: $13.5 million charge.
This million for the year to December 31, 2013 impairment charges of $126.7 million comprised a credit of $159.1 million 2012: 14% of product sales, up from $585.8 related to RESOLOR intangible assets and $9.2 million charge relating to the change million in the corresponding period in 2012 higher legal and litigation costs, including in fair values of contingent consideration 14% of product sales.
The costs of acharge of $57.5 million in relation to the liabilities, in particular relating to the product sales as a percentage of product agreement in principle with the US acquisition of SARcode, partially offset by sales remained broadly constant in 2013 Government.
Excluding these costs SG&A $25.0 million of acquisition and integration as compared to 2012. decreased by $43.1 million or 3% due to costs, primarily for the acquisition of the Companys continuing focus on For the year to December 31, 2013 cost ViroPharma and integration of SARcode simplifying its business and delivering ofproduct sales included depreciation and Lotus Tissue Repair.
and acquisition costs was primarily related For the year to December 31, 2013 SG&A to the acquisition of FerroKin.
R&D from continuing operations included depreciation of $66.8 million R&D expenditure decreased to $933.4 Interest expense from continuing 2012: $57.5 million and amortization of million for the year to December 31, 2013 operations $152.0 million 2012: $153.6 million.
20% of product sales, compared to For the year to December 31, 2013 the $953.0 million in the corresponding period Goodwill impairment charges from Company incurred interest expense of in 2012 22% of product sales.
In the year continuing operations $38.1 million 2012: $38.2 million.
Interest to December 31, 2012 R&D included In the first quarter of 2013 Shire recorded expense principally related to the coupon up-front payments of $13.0 million to agoodwill impairment charge of $198.9 and amortization of issue costs on the Sangamo and $10.0 million to acquire the million 2012: $nil in relation to the former Bonds which were fully redeemed or US rights for prucalopride marketed in RM business unit.
Following a review of converted in the year, and to a lesser certain countries in Europe as RESOLOR future forecasts for the RM business unit, extent costs incurred on facilities related and IPR&D impairment charges in respect management determined in the first tothe purchase of ViroPharma.
of RESOLOR of $71.2 million 2013: $19.9 quarter of 2013 that future sales were million.
Excluding these costs R&D expected to be lower than anticipated at increased by $54.7 million or 6% in the the time of acquisition and consequently year to December 31, 2013 due to the inaccordance with US GAAP, it was 40 SHIRE PLC ANNUAL REPORT 2013 WWW.
COM Governance Financial statements Other information Strategic report Taxation from continuing operations Convertible Bonds An important part of Shires business The effective tax rate was 16% 2012: As of December 31, 2013, Bondholders strategy is to protect its products and 20%.
had voluntarily converted $1,099,050,000 technologies through the use of patents, aggregate principal amount of the Bonds proprietary technologies and trademarks, The effective tax rate is lower than 2012 into 33,806,464 fully paid Ordinary Shares.
The Company primarily due to the impact of changes in The remaining outstanding Bonds in an intends to defend its intellectual property the fair values of contingent consideration aggregate principle amount of $950,000 and as a result may need cash for funding liabilities which have no tax impact and were redeemed pursuant to the Optional the cost of litigation.
impairment charges in 2012 which had no Redemption Notice issued on November tax benefit and were not repeated in 2013.
The Company finances its activities 26, 2013. through cash generated from operating Discontinued operations Non-current deferred tax liabilities activities: credit facilities: private and The loss from discontinued operations Non-current deferred tax liabilities publicofferings of equity and debt forthe year to December 31, 2013 was increased by $39.8 million to $560.6 million securities: and the proceeds of asset $754.5 million net of tax 2012: $60.3 December 31, 2012: $520.8 million, orinvestment disposals.
million, which included impairment primarily due to deferred tax liabilities charges in respect of the assets held for Shires balance sheet includes $2,239.4 arising on the IPR&D assets acquired sale $636.9 million, goodwill impairment million of cash and cash equivalents at withSARcode and Lotus offset by a charges $191.8 million, net losses on the December 31, 2013.
Shire has a revolving reduction in deferred tax liabilities arising discontinued DERMAGRAFT business credit facility of $1,200 million which from the impairment of DERMAGRAFT $252.2 million including reorganization matures in 2015, of which $700 million intangible assets.
costs and related taxes credits of wasutilized on January 24, 2014 to $326.4million.
Other non-current liabilities partially fund the ViroPharma acquisition Other non-current liabilities increased by See section Term Loan, Facilities Financial condition at December 31, $346.9 million to $588.5 million December Agreement for further details.
In addition 2013 31, 2012: $241.6 million primarily due to in connection with its acquisition of Cash & cash equivalents the recognition of non-current contingent ViroPharma, Shire entered into a $2.60 Cash and cash equivalents increased consideration payable related to the billion Facilities Agreement which was by$757.2 million to $2,239.4 million SARcode, Premacure and Lotus business subsequently reduced to $1.40 billion, December 31, 2012: $1,482.2 million.
andcomprises of two credit facilities: Cash generated by operating activities of i a$0.55 billion term loan facility, of which $1,463.0 million was offset by the cost of Liquidity and capital resources $0.35 billion was utilized on January 24, acquiring SARcode, Premacure and Lotus, General 2014 and ii a $0.85billion term loan the purchase of shares both by the The Companys funding requirements facility, fully utilized on January 24, 2014 employee benefit trust EBT and under depend on a number of factors, including See section Term Loan Agreement for the share buy-back program, other capital the timing and extent of its development further details.
Further on January 24, expenditure and dividend payments.
programs: corporate, business and 2014 ViroPharma commenced a tender product acquisitions: the level of resources offer to repurchase, at the option of each Accounts receivable, net required for the expansion of certain holder, any and all ofViroPharmas Accounts receivable, net increased by manufacturing and marketing capabilities outstanding 2.00% Convertible Senior $137.0 million to $961.2 million December as the product base expands: increases Notes Due 2017 theConvertible Notes 31, 2012: $824.2 million, primarily due to inaccounts receivable and inventory which and notified the holders of their separate the increase in revenue in the year to may arise with any increase in product right to convert the Convertible Notes.
Days sales sales: competitive and technological repurchase and payment for conversion of outstanding decreased to 46 days developments: the timing and cost of the Convertible Notes forms part of the December 31, 2012: 50 days.
obtaining required regulatory approvals cash consideration payable to ViroPharma.
fornew products: the timing and quantum Other intangible assets, net of milestone payments on collaborative Shire 2.75% Convertible Bonds due 2014 Other intangible assets increased by projects: the timing and quantum of tax On May 9, 2007 Shire issued $1,100 million $75.5million to $2,312.6 million December and dividend payments: the timing and in principal amount of Bonds.
As of 31, 2012: $2,388.1 million, due to the quantum of purchases by the EBT of December 31, 2013 all of the Bonds IPR&D assets acquired with SARcode, Shireshares in the market to satisfy hadbeen converted or redeemed as Premacure and Lotus, offset by the awards granted under Shires employee described below.
divestment of DERMAGRAFT intangible share plans: and the amount of cash assets, intangible asset amortization, generated from sales of Shires products IPR&D impairment and foreign exchange and royalty receipts.
COM ANNUAL REPORT 2013 SHIRE PLC 41 Review of our business continued On November 26, 2013, Shire issued an The interest rate on each loan drawn under On December 13, 2013 and on February optional redemption notice under the Trust the RCF for each interest period is the 21, 2014, the Company cancelled part of Deed to the holders of the Bonds.
The percentage rate per annum which is the the $2.60 billion term loan facility.
The aggregate outstanding principal amount aggregate of the applicable margin revised Facilities Agreement of $1.40 billion ofBonds on November 25, 2013, the last ranging from 0.90 to 2.25 per cent per now comprises two credit facilities: i a practicable date prior to the date of the annum and LIBOR for the applicable $0.55 billion term loan facility and ii a optional redemption notice, was currency and interest period.
Shire also $0.85 billion term loan facility.
The last day on which pays a commitment fee on undrawn terms and conditions remain unchanged.
bondholders were able to exercise their amounts at 35 per cent per annum The $0.55 billion term loan facility, which conversion rights was December 13, 2013. oftheapplicable margin.
matures on November 10, 2014, may be Those Bonds which were not voluntarily Under the RCF it is required that i Shires used only to finance the purchase price converted were redeemed by the ratio of Net Debt to EBITDA as defined payable in respect of Shires acquisition Company on December 27, 2013 at par within the RCF agreement does not ofViroPharma including certain related together with interest accrued to that date.
exceed 3.5 to 1 for either the 12 month costs and for the redemption of Shires As of December 31, 2013, Bonds in an period ending December 31 or June 30 Bonds.
Shire has the option to extend aggregate principal amount of the unless Shire has exercised its option thematurity of the $0.55 billion term loan $1,099,050,000 had been voluntarily which is subject to certain conditions to facility once by a further 364 days.
converted into 33,806,464 fully paid increase it to 4.0 to 1 for two consecutive Ordinary Shares at a conversion price The $0.85 billion term loan facility, which testing dates: ii the ratio of EBITDA to Net ofUS$32.51 per Ordinary Share, in the matures on November 11, 2015, may Interest as defined in the RCF agreement capital of the Company, with par value beused only to finance the purchase must not be less than 4.0 to 1, for either of0.05 each.
The remaining outstanding pricepayable in respect of Shires the 12 month period ending December 31 Bonds in an aggregate principle amount acquisition ofViroPharma including or June 30, and iii additional limitations on of$950,000 were redeemed pursuant certainrelated costs.
the creation of liens, disposal of assets, tothe Optional Redemption Notice issued incurrence of indebtedness, making of Interest on any loans made under the on November 26, 2013.
Following the loans, giving of guarantees and granting facilities will be payable on the last day redemption of all the outstanding Bonds, security over assets.
These financial and ofeach interest period, which may be the Company cancelled the listing of operating covenants have not had, and are oneweek or one, two, three or six months theBonds on the Official List maintained not expected to have, an effect on the at the election of Shire, or as otherwise bythe UK Listing Authority and the Companys financial position and liquidity.
The interest rate admission to trading of the Bonds applicable to the $0.55 billion term loan ontheProfessional Securities Market On entering into the RCF in November facility is LIBOR plus 0.75% per annum oftheLondon Stock Exchange.
2010 the Company paid arrangement andincreases by 0.25% per annum on costs of $8.0 million, which have been Revolving Credit Facilities Agreement August 11, 2014 and on three-month recorded as deferred charges, with On November 23, 2010, the Company intervals thereafter.
amortization of these costs to the entered into a committed multicurrency Companys income statement over the The interest rate applicable to the revolving and swingline facilities agreement contractual term of the RCF.
$0.85billion term loan facility commenced with a number of financial institutions, for at LIBOR plus 1.15% per annum until which Abbey National Treasury Services The availability of loans under the new delivery of the compliance certificate for Plc trading as Santander Global Banking RCFis subject to customary conditions.
the year ending December 31, 2013 and and Markets, Bank of America Securities Term Loan Agreement thereafter is subject to change depending Limited, Barclays Capital, Citigroup Global On November 11, 2013, Shire entered into upon the prevailing ratio of Net Debt to Markets Limited, Lloyds TSB Bank plc a $2.60 billion Facilities Agreement with, EBITDA of the Group each as defined in andThe Royal Bank of Scotland plc among others, Morgan Stanley Bank the Facilities Agreement, in respect of the actedas mandated lead arrangers and International Limited acting as lead most recently completed financial year or bookrunners the RCF.
The RCF is for arranger and agent the Facilities financial half year.
anaggregate amount of $1,200 million Agreement.
The Facilities Agreement andcancelled theCompanys then comprises two credit facilities: i a $1.75 existingcommitted revolving credit facility.
billion term loan facility and ii a $0.85 The RCF, which includes a $250 million billion term loan facility.
swingline facility, may be used for general corporate purposes and matures on November 23, 2015.
42 SHIRE PLC ANNUAL REPORT 2013 WWW.
COM Governance Financial statements Other information Strategic report Shire shall also pay a commitment fee on changes in the business, operations, Share buy-back program the available but unutilized commitments assets or financial condition of Shire and Shire has a strong balance sheet and under the $0.55 billion term loan facility itssubsidiaries, vii if it becomes unlawful continued robust cash generation, and and the $0.85 billion term loan facility for for Shire or any of its subsidiaries that are considers efficient use of capital on behalf the availability period applicable to each parties to the Facilities Agreement to ofshareholders an important objective.
With effect from first utilization, the perform their obligations or viii if Shire or Therefore, during the year to December 31, commitment fee rate will be 35% of the any subsidiary of Shire which is a party to 2012 the Company commenced a share applicable margin.
Before first utilization, the Facilities Agreement repudiates the buy-back program, for the purpose of the commitment fee rate will increase in Facilities Agreement or any other finance returning funds to shareholders, of up stages from 0% to 35% of the applicable document, among others.
to$500 million through both direct margin over a period of 3 months.
purchases of Ordinary Shares and The Facilities Agreement is governed by throughthe purchase of Ordinary Shares The Facilities Agreement includes English law.
customary representations and warranties, Financing covenants and events of default, including During the year ended December 31, 2013, Shire anticipates that its operating cash requirements that the ratio of Net Debt to the Company made on-market repurchases flow together with available cash, cash EBITDA of the Group each as defined in totaling 6,191,965 Ordinary Shares at a equivalents and, the RCF will be sufficient the Facilities Agreement must not, at any cost of $193 million excluding transaction to meet its anticipated future operating time, exceed 3.5:1 for the Relevant Period costs.
The program covers purchases of expenses, capital expenditures, tax and as defined in the Facilities Agreement, Ordinary Shares for cancellation or to be interest payments, lease obligations and except that following certain acquisitions, held as treasury shares, in accordance milestone payments as they become due including the Viropharma acquisition, Shire with the authority renewed by shareholders over the next twelve months.
may elect to increase the ratio to 4.0:1 in at the Companys AGM on April 30, 2013 the relevant period in which the acquisition when the Company was authorized to Shires existing cash, the Facilities was completed and the immediately make market purchases of up to Agreement and the RCF are sufficient to following relevant period.
In addition, for 55,741,587 ofitsown Ordinary Shares.
finance the acquisition of ViroPharma.
each 12-month period ending December On November 11, 2013, contemporaneous If the Company decides to acquire other 31 or June 30, the ratio of EBITDA of the with Shires announcement of its businesses in addition to ViroPharma, it Group to Net Interest each as defined in acquisition of ViroPharma, the Companys expects to fund these acquisitions from the Facilities Agreement must not be less share buyback program was terminated.
cash resources, the RCF and possibly than 4.0:1.
Since the inception of the share buyback through new borrowings or the issuance The Facilities Agreement restricts subject program the Company had purchased ofnew equity if necessary.
to certain covenants Shires ability to incur $300 million of Ordinary Shares and additional financial indebtedness, grant Ordinary Shares underlying ADRs.
security over its assets or provide or Sources and uses of cash guarantee loans.
Further, any lender may The following table provides an analysis of the Companys gross and net cash require mandatory prepayment of its excluding restricted cash, as at December 31, 2013 and 2012: participation if there is a change of control of Shire.
In addition, in certain 2013 2012 circumstances, the net proceeds of certain December 31, $M $M shares, undertakings or business 1 Cash and cash equivalents 2,239.4 1,482.2 disposals by Shire must be applied Shire 2.75% Convertible bonds 1,100.0 towards the mandatory prepayment of the Other debt 8.9 9.3 facilities, subject to certain exceptions.
Total debt 8.9 1,109.3 Events of default under the facilities include: i non-payment of any amounts Net cash 2,230.5 372.9 due under the facilities, ii failure to satisfy any financial covenants, iii material 1 Substantially all of the Companys cash and cash equivalents are held by foreign subsidiaries i. e, those misrepresentation in any of the finance subsidiaries incorporated outside of Jersey, Channel Islands, the jurisdiction of incorporation of Shire plc, documents, iv failure to pay, or certain Shires holding company.
The amount of cash and cash equivalents held by foreign subsidiaries has not had, and is not expected to have, a material impact on the Companys liquidity and capital resources.
other defaults, under other financial indebtedness, v certain insolvency events Net cash is a Non GAAP measure.
The Company believes that Net cash is a useful measure as it indicates or proceedings, vi material adverse the level of borrowings after taking account the cash and cash equivalents that could be utilized to pay down the outstanding borrowings.
COM ANNUAL REPORT 2013 SHIRE PLC 43 Review of our business continued Cash flow activity Net cash used in investing activities was 2013, principally due to the purchase of Net cash provided by operating activities $360.9 million in the year to December 31, shares under the share buy-back program, for the year to December 31, 2013 2013, principally relating to the cash paid purchase of shares by the EBT and the increased by $80.1 million or 6% to net of cash acquired for the acquisitions dividend payment.
$1,463.0 million 2012: $1,382.9 million as of SARcode, Premacure and Lotus Tissue Net cash used in financing activities was higher cash receipts from gross product Repair and for purchases of PP&E.
$244.3 million for the year to December 31, sales were more than offset by payments Net cash used in investing activities was 2012, principally due to the purchase of made in relation to the One Shire $271.0 million in the year to December 31, shares by the EBT, the purchase of shares reorganization approximately $42 million, 2012, principally relating to the expenditure under the share buy-back program and costs incurred on the closure of Shires on property, plant and equipment of dividend payments, offset by the tax facility at Turnhout in Belgium $149.6 million and the cash paid net of benefit associated with the exercise of approximately $24 million and the cash acquired of $97.0 million for the stock options.
payment to settle the litigation with Impax acquisition of FerroKin $94.5 million and $48 million see Note 19 for details.
Outstanding letters of credit Pervasis $2.5 million.
Capital expenditure At December 31, 2013, the Company had Net cash provided by operating activities on property, plant and equipment primarily irrevocable standby letters of credit and for the year to December 31, 2012 includes expenditure of $65.0 million on guarantees with various banks totaling increased by $309.3 million or 29% to computer software and hardware due to $51.3 million, providing security for the $1,382.9 million 2011: $1,073.6 million as SAP upgrade and construction and Companys performance of various higher cash receipts from gross product leasehold improvements at different obligations.
These obligations are primarily sales and improved cash collections for Company sites of $45.2 million.
in respect of the recoverability of insurance aged European receivables more than Net cash used in financing activities was claims, lease obligations and supply offset higher operating expenses and sales $344.6 million for the year to December 31, commitments.
deduction payments in the year.
Cash requirements At December 31, 2013 the Companys cash requirements for long term liabilities reflected on the Balance Sheet and other contractual obligations were as follows: Payments due by period Less than More than Total 1 year 1-3 years 3-5 years 5years $M $M $M $M $M i Operating leases obligation 215.9 44.9 57.5 30.1 83.4 ii Purchase obligations 609.8 500.1 96.2 11.9 1.6 iii Other long term liabilities reflected on the Balance Sheet 578.5 375.3 72.6 130.6 Total 1,404.2 545.0 529.0 114.6 215.6 i The Company leases certain land, iii Unrecognized tax benefits and i Research Collaboration with Santaris facilities, motor vehicles and certain associated interest and penalties of $115.7 Pharma A S Santaris on Locked Nucleic equipment under operating leases expiring million are included within payments due in Acid LNA Drug Platform through 2021. one to three years.
On August 24, 2009, Shire announced that it had entered into a research collaboration ii Purchase obligations include The contractual obligations table above with Santaris, to develop its proprietary agreements to purchase goods, does not include certain milestones and LNA technology in a range of rare investments or services including clinical other contractual commitments where diseases.
LNA technology has the benefit trials, contract manufacturing and capital payment is contingent upon the of shortened target validation and proof of equipment, including open purchase occurrence of events which are yet to concept, potentially increasing the speed orders, that are enforceable and legally occur and therefore payment is not yet and lowering the cost of development.
As binding and that specify all significant due.
At December 31, 2013 the most part of the joint research project Santaris terms.
Shire expects to fund these significant of the Companys milestone and will design, develop and deliver pre-clinical commitments with cash flows from contractual commitments which are LNA oligonucleotides for Shire-selected operating activities.
contingent on the occurrence of future orphan disease targets, and Shire will have events are as follows: the exclusive right to further develop and commercialize these candidate compounds on a worldwide basis.
44 SHIRE PLC ANNUAL REPORT 2013 WWW.
COM Governance Financial statements Other information Strategic report In the year to December 31, 2013, Shire $159.3 million, comprising cash consideration paid on closing of $30.6 paid success milestones and other consideration paid on closing of $94.5 million, and the fair value of contingent support costs of $1.5 million 2012: $3.0 million and the fair value of contingent consideration payable of $109.6 million.
million: and $4.5 million 2012: $8.1 million consideration payable of $64.8 million.
The maximum amount of contingent cash to Santaris respectively, which were Themaximum amount of contingent cash consideration which may be payable by expensed to R&D.
Shire has remaining consideration which may be payable by Shire in future periods, dependent upon obligations to pay Santaris development Shire in future periods is $225.0 million.
the successful completion of certain and sales milestones up to a maximum The amount of contingent cash development and commercial milestones, of$71.0 million for current indication.
Shire consideration ultimately payable by Shire is $169 million.
Shire will also pay royalties will also pay single or double digit tiered isdependent upon the achievement of on relevant net sales.
For further details royalties on net sales of the product.
certain clinical development, regulatory refer to Note 4 of this Annual Report.
For further Shire and Santaris have formed a joint vii Acquisition of SARcode details refer to Note 4 of this Annual Report.
research committee to monitor R&D On April 17, 2013 Shire completed the activities through preclinical lead candidate iv Acquisition of certain assets & liabilities acquisition of 100% of the outstanding selection at which point all development ofPervasis share capital of SARcode.
The acquisition and commercialization costs will be the On April 19, 2012, Shire acquired date fair value of the consideration totaled responsibility of Shire.
substantially all the assets and certain $368 million, comprising cash liabilities of Pervasis.
The acquisition date consideration paid on closing of $151 ii Collaboration and license agreement with fair value of the consideration totaled $26.1 million and the fair value of contingent Sangamo to develop therapeutics for million, comprising cash consideration paid consideration payable of $217 million.
hemophilia on closing of $2.5 million and the fair value Themaximum amount of contingent On February 1, 2012 Shire and Sangamo of contingent consideration payable of cashconsideration which may be payable announced that they had entered into a $23.6 million.
The maximum amount of by Shire in future periods is $225 million collaboration and license agreement to contingent cash consideration which may dependent upon achievement of certain develop therapeutics for hemophilia and be payable by Shire in future periods is clinical, regulatory and net sales other monogenic diseases based on $169.5 million.
The amount of contingent milestones.
For further details refer Sangamos ZFP technology.
Sangamo cash consideration ultimately payable by toNote4 of this Annual Report.
isresponsible for all activities through Shire is dependent upon achievement of submission of Investigational New Drug viii Acquisition of ViroPharma certain clinical development, regulatory Applications and European Clinical Trial On November 11, 2013, Shire signed a and net sales milestones.
For further Applications for each product and Shire definitive agreement to acquire all of the details refer to Note 4 of this Annual Report.
will reimburse Sangamo for its internal outstanding share capital of ViroPharma andexternal research program-related v Acquisition of Lotus Tissue Repair for $50 per share in cash or approximately costs.
Shire is responsible for clinical On February 12, 2013 Shire completed $4.2 billion.
The transaction was development and commercialization of theacquisition of 100% of the outstanding completed on January 24, 2014 at which products arising from the collaboration.
share capital of Lotus Tissue Repair.
The time ViroPharma became a wholly-owned acquisition date fair value of consideration subsidiary.
Shires consolidated financial In the year to December 31, 2012 Shire totaled $174.2 million, comprising cash statements will reflect the fair values of made an upfront payment to Sangamo consideration paid on closing of $49.4 assets acquired and the liabilities assumed of$13.0 million, for technology access million, and the fair value of contingent at, and the results of ViroPharma will be andR&D funding, which was expensed consideration payable of $124.8 million.
included in Shires consolidated statement toR&D.
The maximum amount of contingent cash of income from, January 24, 2014.
Further consideration which may be payable by on January 24, 2014 ViroPharma In the year to December 31, 2013 Shire in future periods is $275 million.
The commenced a tender offer to repurchase, Shiresshare of R&D costs under this amount of contingent cash consideration at the option of each holder, any and all of collaboration agreement was $15.2 million ultimately payable by Shire is dependent ViroPharmas Convertible Notes and 2012: $8.9 million which were expensed upon achievement of certain pre-clinical notified the holders of their separate right to R&D.
Shire may be required to pay and clinical development milestones.
to convert the Convertible Notes.
The research, regulatory, development and Forfurther details refer to Note 4 of this repurchase and payment for conversion of commercial milestone payments up to a Annual Report.
the Convertible Notes forms part of the maximum of $213.5 million and to pay cash consideration payable to ViroPharma.
royalties on net sales of the product.
vi Acquisition of Premacure For further details refer to Note 4 of this On March 8, 2013 Shire completed the iii Acquisition of FerroKin Annual Report.
acquisition of 100% of the outstanding On April 2, 2012 Shire completed the share capital of Premacure.
The acquisition acquisition of 100% of the outstanding date fair value of the consideration totaled share capital of FerroKin.
The acquisition- $140.2 million, comprising cash date fair value of consideration totaled WWW.
COM ANNUAL REPORT 2013 SHIRE PLC 45 Review of our business continued Off-balance sheet arrangements The Company is exposed to the credit risk TheCompany continued to receive There are no off-balance sheet of the counterparties with which it enters remittances in relation to , aside from the into derivative instruments.
The Company owned or government-supported collaborations containing contractual limits this exposure through a system of healthcare providers in all the Relevant commitments and milestones which are internal credit limits which vary according Countries in the year to December 31, contingent on future events as outlined to ratings assigned to the counterparties 2013, including receipts of $116.8 million above, that have, or are reasonably likely by the major rating agencies.
The internal and $144.7 million in respect of Spanish tohave, a current or future material effect credit limits are approved by the Board and Italian receivables, respectively.
on the Companys financial condition, and exposure against these limits is To date the Company has not incurred revenues or expenses, results of monitored by the corporate treasury significant losses on accounts receivable in operations, liquidity, capital expenditures function.
The counterparties to these the Relevant Countries, and continues to or capital resources.
derivatives contracts are major consider that such accounts receivable are international financial institutions.
The Company will continue to A number of the Companys subsidiaries The Companys revenues from product evaluate all its accounts receivable for have a functional currency other than the sales in the US are mainly governed by potential collection risks and has made US Dollar.
As such, the consolidated agreements with major pharmaceutical provision for amounts where collection is financial results are subject to fluctuations wholesalers and relationships with other considered to be doubtful.
If the financial in exchange rates, particularly in the Euro, pharmaceutical distributors and retail condition of the Relevant Countries or Swiss Franc and Pound Sterling against pharmacy chains.
For the year to other Eurozone countries suffer significant the US Dollar.
December 31, 2013 there were three deterioration, such that their ability to make customers in the US that accounted for payments becomes uncertain, or if one The accumulated foreign currency 52% of the Companys product sales.
ormore Eurozone member countries translation differences at December 31, However, such customers typically have withdraws from the Euro, additional 2013 of $25.3 million are reported within significant cash resources and as such allowances for doubtful accounts may accumulated other comprehensive income therisk from concentration of credit is berequired, and losses may be incurred, in the consolidated balance sheet and considered acceptable.
The Company has in future periods.
Any such loss could foreign exchange losses for the year to taken positive steps to manage any credit havean adverse effect on the Companys December 31, 2013 of $8.7 million are risk associated with these transactions and financial condition and results of operations.
reported in the consolidated statements operates clearly defined credit evaluation ofincome.
However, an inability of one or Although at reduced levels in recent years, more of these wholesalers to honor their At December 31, 2013, the Company had inflation continues to apply upward debts to the Company could have an outstanding swap and forward foreign pressure on the cost of goods and adverse effect on Companys financial exchange contracts to manage the services which are used in the business.
condition and results of operations.
currency risk associated with However, the Company believes that the intercompany transactions.
At December A substantial portion of the Companys net effect of inflation on its revenues and 31, 2013 the fair value of these contracts accounts receivable in countries outside of operations has been minimal during the was a net asset of $1.2 million.
the United States is derived from product past three years.
sales to government-owned or Concentration of credit risk government-supported healthcare Financial instruments that potentially providers.
The Companys recovery of expose Shire to concentrations of credit these accounts receivable is therefore risk consist primarily of short term cash dependent upon the financial stability and investments, derivative contracts and trade creditworthiness of the relevant accounts receivable from product sales governments.
In recent years the and from third parties from which the creditworthiness and general economic Company receives royalties.
Cash is condition of a number of Eurozone invested in short term money market countries including Greece, Italy, Portugal instruments, including money market and and Spain the Relevant Countries has liquidity funds and bank term deposits.
As a result, in some of these The money market and liquidity funds in countries the Company is experiencing which Shire invests are all triple A rated by delays in the remittance of receivables due both Standard and Poors and by Moodys from government-owned or governmentcredit rating agencies.
46 SHIRE PLC ANNUAL REPORT 2013 WWW.
COM Governance Financial statements Other information Strategic report Treasury policies and organization Foreign exchange risk At December 31, 2013, the Company had The Companys principal treasury The Company trades in numerous 29 swap and forward foreign exchange operations are coordinated by its corporate countries and as a consequence has contracts outstanding to manage currency treasury function.
All treasury operations transactional and translational foreign risk.
The swap and forward contracts are conducted within a framework of exchange exposures.
The Company policies and procedures approved annually didnot have credit risk related contingent Transactional exposure arises where by the Board of Directors.
As a matter of features or collateral linked to the transactions occur in currencies different policy, the Company does not undertake derivatives.
The Company has master to the functional currency of the relevant speculative transactions that would netting agreements with a number of subsidiary.
The main trading currencies of increase its credit, currency or interest counterparties to these foreign exchange the Company are the US Dollar, Pounds rateexposure.
contracts and on the occurrence of Sterling, Swiss Franc and the Euro.
It is the specified events, the Company has the Interest rate risk Companys policy that these exposures ability to terminate contracts and settle The Company is exposed to interest rate are minimized to the extent practicable them with a net payment by one party to risk on its $1,200 million RCF, its $0.55 bydenominating transactions in the the other.
The Company has elected to billion term loan facility, its $0.85 billion subsidiarys functional currency.
present derivative assets and derivative term loan facility the Facilities, to the liabilities on a gross basis in the Where significant exposures remain, the extent the Facilities are utilized, restricted consolidated balance sheet.
As at Company uses foreign exchange contracts cash, cash and cash equivalents and on December 31, 2013 the potential effect of being spot, forward and swap contracts foreign exchange contracts on which rights of set off associated with the foreign to manage the exposure for balance sheet interest is at floating rates.
This exposure is exchange contracts would be an offset to assets and liabilities that are denominated primarily to US Dollar, Pounds Sterling, both assets and liabilities of $0.7 million, in currencies different to the functional Euro and Canadian Dollar interest rates.
resulting in net derivative assets and currency of the relevant subsidiary.
These The Company has evaluated the interest derivative liabilities of $3.3 million and assets and liabilities relate predominantly rate risk on its debt facilities and considers $2.1million, respectively.
Further details to intercompany financing.
The foreign the floating rate as appropriate.
As the areincluded on the next page.
exchange contracts have not been Company maintains all of its cash, liquid designated as hedging instruments.
investments and foreign exchange Cashflows from derivative instruments contracts on a short term basis for liquidity arepresented within net cash provided purposes, this risk is not actively managed.
byoperating activities in the consolidated In the year to December 31, 2013 the cash flow statement, unless the derivative average interest rate received on cash and instruments are economically hedging liquid investments was less than 1% per specific investing or financing activities.
The largest proportion of these cash and liquid investments was in US Translational foreign exchange exposure dollar money market and liquidity funds.
arises on the translation into US Dollars of At December 31, 2013 the Facilities were the financial statements of non-US Dollar not utilized.
No derivative instruments were entered into during the year to December 31, 2013 to manage interest rate exposure.
The Company continues to review its interest rate risk and the policies in place to manage the risk.
COM ANNUAL REPORT 2013 SHIRE PLC 47 Review of our business continued Foreign exchange risk sensitivity The Companys revenues from product The following exchange rate sensitivity analysis summarises the sensitivity of the sales in the US are mainly governed by Companys reported revenues and net income to hypothetical changes in the average agreements with major pharmaceutical annual exchange rates of the Euro, Pound Sterling and Swiss Franc against the US wholesalers and relationships with other Dollar, assuming a hypothetical 10% strengthening of the USDollar against each of the pharmaceutical distributors and retail aforementioned currencies in the year toDecember 31, 2013 : pharmacy chains.
For the year to December 31, 2013 there were three Increase Increase customers in the US that accounted for reduction in reduction in 52% of the Companys product sales.
revenues net income However, such customers typically have $M $M significant cash resources and as such Euro 78 36 therisk from concentration of credit is Pound Sterling 19 7 considered acceptable.
The Company has Swiss Franc 9 taken positive steps to manage any credit risk associated with these transactions and A 10% weakening of the US Dollar against the aforementioned currencies would have operates clearly defined credit evaluation an equal and opposite effect.
However, an inability of one or more of these wholesalers to honor their The table below provides information about the Companys swap and forward foreign debts to the Company could have an exchange contracts by currency pair.
The table presents the net principal amounts and adverse effect on the Companys financial weighted average exchange rates of all outstanding contracts.
All contracts have a condition and results of operations.
maturity date of less than three months.
A substantial portion of the Companys Principal Weighted accounts receivable in countries outside Value of Average of the United States is derived from Amount Exchange product sales to government-owned Receivable Rate Fair Value  healthcare December 31, 2013 $M $M $M providers.
The Companys recovery of Swap foreign exchange contracts these accounts receivable is therefore Receive USD Pay EUR 256.0 1.36 2.2 dependent upon the financial stability Receive GBP Pay USD 158.0 1.62 2.8 andcreditworthiness of the relevant Receive USD Pay JPY 1.6 0.01 governments.
In recent years the Receive SEK Pay USD 24.3 0.15 0.6 creditworthiness and general economic Receive USD Pay MXN 10.4 0.08 condition of the relevant countries has deteriorated.
As a result, in some of these Concentration of credit risk The Company is exposed to the credit risk countries the Company is experiencing Financial instruments that potentially of the counterparties with which it enters delays in the remittance of receivables due expose Shire to concentrations of credit into derivative instruments.
The Company from government-owned or governmentrisk consist primarily of short term cash limits this exposure through a system of supported healthcare providers.
investments, derivative contracts and trade internal credit limits which vary according accounts receivable from product sales to ratings assigned to the counterparties and from third parties from which the by the major rating agencies.
The internal Company receives royalties.
Cash is credit limits are approved by the Board invested in short term money market and exposure against these limits is instruments, including money market and monitored by the corporate treasury liquidity funds and bank term deposits.
The counterparties to these The money market and liquidity funds in derivatives contracts are major which Shire invests are all triple A rated by international financial institutions.
both Standard and Poors and by Moodys credit rating agencies.
48 SHIRE PLC ANNUAL REPORT 2013 WWW.
COM Governance Financial statements Other information Strategic report The Companys aggregate accounts receivable, net of the allowance for doubtful Strategic Report accounts, in total from government-owned or government-supported healthcare The Strategic Report comprises providers in the relevant countries are as follows: pages 4 to 49 of this Annual Report December 31, December 31, and Accounts.
2013 2012 On behalf of the Board December 31, $M $M Total accounts receivable, net in the relevant countries 127 136 Total accounts receivable, net in the relevant countries as apercentage of total outstanding accounts receivable, net 13% 17% Accounts receivable, net due from government-owned  healthcare providers for the Tatjana May relevantcountries 116 129 Company Secretary February 24, 2014 Accounts receivable due from Other than the accounts receivable government-owned or governmentfrom government-owned or supported supported healthcare providers in the healthcare providers outlined above, relevant countries of $116 million 2012: the Company does not hold any other $130 million are split by country as follows: government debt from the relevant Greece $4 million 2012: $6 million : Italy countries.
Additionally the Company $59 million 2012: $62 million : Portugal does not consider it is currently exposed $14million 2012: $13 million and Spain to significant sovereign credit risk outside $39 million 2012: $48 million.
The Company continues to receive The Company continues to evaluate all its remittances in relation to governmentaccounts receivable for potential collection owned or government-supported risks and has made provision for amounts healthcare providers in the relevant where collection is considered to be countries and in the year to December 31, doubtful.
If the financial condition of the 2013 received $284.9 million in settlement relevant countries or other Eurozone of accounts receivable in the relevant countries suffer significant deterioration, countries $9.5 million was from Greece: such that their ability to make payments $145.0 million from Italy: $13.4 million from becomes uncertain, or if one or more Portugal and $117.0 million from Spain.
Eurozone member countries withdraws from the Euro, additional allowances for To date the Company has not incurred doubtful accounts may be required, and significant losses on the accounts losses may be incurred, in future periods.
receivable in the relevant countries, Any such loss could have an adverse andcontinues to consider that such effect on the Companys financial condition accounts receivable are recoverable.
COM ANNUAL REPORT 2013 SHIRE PLC 49 50 SHIRE PLC ANNUAL REPORT 2013 WWW.
COM Strategic report Governance Financial statements Other information From the way we work together to the distinctivequalities of our treatments, we striveforexcellence throughout our business.
Our work exploring how LDX, the active ingredient in VYVANSE, can be used to treatBEDis a great example of how we aim toexcel by building on our strengths and, asever, focusing on people with high unmet specialist needs.
Were working on extending LDX to treat adults with BED 1 BED in adults is a huge unmet need and according to 5 Of those that are diagnosed not all are being treated physicians there are few treatments of any kind available 2 The seriousness of the disorder is increasingly 6 Health care practitioners are generally dissatisfied with acknowledged in the physician community themixed results from the current treatment options thatinclude counseling and cognitive behavioral therapy, or off label anti-depressant and anti-psychotic drugs The market is ready for a safe and effective treatment 3 With the two pivotal Phase 3 eating disorder trials now 7 fullyenroled, our Phase 3 program is ahead of schedule 4 Estimates suggest that there are around 3 million adultswith BED in the US and about 9 out of 10 ofthemare undiagnosed WWW.
COM ANNUAL REPORT 2013 SHIRE PLC 51
